A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
Open Access
- 6 June 2022
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-15
Abstract
Objective. Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods. Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. Results. By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. Conclusion. The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.Keywords
Funding Information
- Key Innovative Project in Shaanxi (2021ZDLSF02-02, 2020SF-204, 2019SF-059, ZR2020QH0233, 31570906, 81671476, 81802486, 81402049)
- key research and development plan in Shaanxi (2021ZDLSF02-02, 2020SF-204, 2019SF-059, ZR2020QH0233, 31570906, 81671476, 81802486, 81402049)
- Natural Science Foundation of Shandong Province (2021ZDLSF02-02, 2020SF-204, 2019SF-059, ZR2020QH0233, 31570906, 81671476, 81802486, 81402049)
- National Natural Science Foundation of China (2021ZDLSF02-02, 2020SF-204, 2019SF-059, ZR2020QH0233, 31570906, 81671476, 81802486, 81402049)
This publication has 39 references indexed in Scilit:
- Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-AnalysisPLOS ONE, 2013
- Pseudogenes: Newly Discovered Players in Human CancerScience Signaling, 2012
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited SettingPLOS ONE, 2012
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Generalized Maximally Selected StatisticsBiometrics, 2008
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Adjusting batch effects in microarray expression data using empirical Bayes methodsBiostatistics, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005